S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:ALT

Altimmune (ALT) Stock Price, News & Analysis

$8.89
+0.24 (+2.77%)
(As of 03/27/2024 ET)
Today's Range
$7.92
$9.68
50-Day Range
$8.22
$13.81
52-Week Range
$2.09
$14.84
Volume
11.12 million shs
Average Volume
4.71 million shs
Market Capitalization
$477.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.75

Altimmune MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
77.2% Upside
$15.75 Price Target
Short Interest
Bearish
23.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.12mentions of Altimmune in the last 14 days
Based on 18 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.43) to ($1.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.32 out of 5 stars

Medical Sector

760th out of 939 stocks

Pharmaceutical Preparations Industry

352nd out of 431 stocks

ALT stock logo

About Altimmune Stock (NASDAQ:ALT)

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

ALT Stock Price History

ALT Stock News Headlines

Q4 2023 Altimmune Inc Earnings Call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Here's what Wall Street expects from Altimmune's earnings report
(ALT) - Analyzing Altimmune's Short Interest
Altimmune (NASDAQ: ALT)
UroGen Pharma Q4 2023 Earnings Preview
See More Headlines
Receive ALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALT
Employees
52
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.75
High Stock Price Target
$20.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+77.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-84,710,000.00
Pretax Margin
-28,124.01%

Debt

Sales & Book Value

Annual Sales
$4.41 million
Book Value
$3.77 per share

Miscellaneous

Free Float
51,526,000
Market Cap
$477.66 million
Optionable
Optionable
Beta
0.08
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Vipin K. Garg Ph.D. (Age 66)
    President, CEO & Director
    Comp: $916.16k
  • Mr. Richard I. Eisenstadt M.B.A. (Age 66)
    Chief Financial Officer
    Comp: $619.69k
  • Dr. M. Scot Roberts Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $599.25k
  • Dr. Matthew Scott Harris AGAF (Age 71)
    FCAP, M.D., MS, Chief Medical Officer
    Comp: $643.04k
  • Mr. Bertrand Georges Ph.D.
    Chief Technology Officer
  • Mr. Tony Blandin B.S.
    Vice President of Quality & Compliance Management
  • Mr. Raymond M. Jordt M.B.A. (Age 51)
    Chief Business Officer
  • Mr. Andrew Shutterly M.S.
    Corporate Controller

ALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Altimmune stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALT shares.
View ALT analyst ratings
or view top-rated stocks.

What is Altimmune's stock price target for 2024?

4 brokers have issued twelve-month target prices for Altimmune's shares. Their ALT share price targets range from $13.00 to $20.00. On average, they predict the company's stock price to reach $15.75 in the next twelve months. This suggests a possible upside of 77.2% from the stock's current price.
View analysts price targets for ALT
or view top-rated stocks among Wall Street analysts.

How have ALT shares performed in 2024?

Altimmune's stock was trading at $11.25 at the start of the year. Since then, ALT stock has decreased by 21.0% and is now trading at $8.89.
View the best growth stocks for 2024 here
.

Are investors shorting Altimmune?

Altimmune saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 12,510,000 shares, an increase of 15.7% from the February 29th total of 10,810,000 shares. Based on an average trading volume of 6,610,000 shares, the days-to-cover ratio is presently 1.9 days.
View Altimmune's Short Interest
.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.45. The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.11 million. During the same period last year, the business earned ($0.54) earnings per share.

When did Altimmune's stock split?

Altimmune's stock reverse split on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Altimmune own?
Who are Altimmune's major shareholders?

Altimmune's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.65%), Vanguard Group Inc. (6.65%), Nuveen Asset Management LLC (3.21%), Point72 Asset Management L.P. (2.32%), Timelo Investment Management Inc. (1.51%) and Goldman Sachs Group Inc. (0.98%). Insiders that own company stock include David Drutz, Diane Jorkasky, M Scot Roberts, Matthew Scott Harris, Vipin K Garg and Wayne Pisano.
View institutional ownership trends
.

How do I buy shares of Altimmune?

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners